Phase IV Trial Probes Acamprosate's Neural Mechanisms in AUD via EEG Beta Power — Implications for Personalised Treatment

References

1. 1.National Institute on Alcohol Abuse and Alcoholism (NIAAA). (2024). Temporally-resolved electrophysiology of acamprosate treatment of alcohol use disorder (NCT06269627). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06269627
2. 2.Maisel, N. C., Blodgett, J. C., Wilbourne, P. L., Humphreys, K., & Finney, J. W. (2013). Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: When are these medications most helpful? Addiction, 108(2), 275–293. https://doi.org/10.1111/j.1360-0443.2012.04054.x
3. 3.Bates, M. E., Buckman, J. F., & Nguyen, T. T. (2013). A role for cognitive rehabilitation in increasing the effectiveness of treatment for alcohol use disorders. Neuropsychology Review, 23(1), 27–47. https://doi.org/10.1007/s11065-013-9228-3
4. 4.Rangaswamy, M., & Porjesz, B. (2014). Understanding alcohol use disorders with neuroelectrophysiology. Handbook of Clinical Neurology, 125, 383–414. https://doi.org/10.1016/B978-0-444-62619-6.00019-X
5. 5.GBD 2016 Alcohol Collaborators. (2018). Alcohol use and burden for 195 countries and territories, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. The Lancet, 392(10152), 1015–1035. https://doi.org/10.1016/S0140-6736(18)31310-2
6. 6.Krupitsky, E. M., Burakov, A. M., Romanova, T. N., Grinenko, N. I., Grinenko, A. Y., Fletcher, J., & Petrakis, I. L. (2007). Attenuation of cue-induced alcohol craving and autonomic reactivity by naltrexone in recently detoxified alcoholics. Addiction, 102(7), 1099–1107. https://doi.org/10.1111/j.1360-0443.2007.01840.x